<DOC>
	<DOCNO>NCT00889369</DOCNO>
	<brief_summary>The main objective study characterize range brain activation symptom associate major depression peri- post-menopausal woman . Also , assess brain activation treatment might help uncover mechanism associate pathophysiology depression menopause .</brief_summary>
	<brief_title>Duloxetine Major Depression Peri-/Postmenopausal Women</brief_title>
	<detailed_description>Women approach menopause post-menopausal year appear great risk develop major depressive episode . Moreover , period life associate significant functional impairment due presence/severity vasomotor symptom ( hot flash , night sweat ) , cognitive complaint , poor quality life . In light recent controversy involve use hormone therapy , physician patient seek nonhormonal strategy alleviate menopause-related physical emotional complaint . Duloxetine show improve major depressive disorder ( MDD ) menopause-related symptom . To date , effect agent brain structure function midlife woman MDD explore . The present study aim investigate effect duloxetine brain structure function use treatment major depressive episode menopausal woman use anatomical magnetic resonance imaging ( MRI ) functional MRI ( fMRI ) . In addition , investigator examine whether impact treatment duloxetine vasomotor symptom , cognition , quality life modulate putative change brain structure functioning .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>peri/postmenopausal woman , age 4060 year moderate severe major depressive episode DSMIV Axis I diagnosis MDD contraindication magnetic resonance image treatmentresistent previous fail treatment duloxetine history substance abuse dependence past year serious suicidal risk use psychotropic medication electroconvulsive therapy transmagnetic stimulation past year history allergic reaction duloxetine significant laboratory abnormality baseline severe hepatic impairment end stage renal disease undergoing dialysis uncontrolled narrowangle glaucoma uncontrolled untreated hyper/hypothyroidism , abnormal thyroid stimulate hormone concentration</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>depression</keyword>
	<keyword>duloxetine</keyword>
	<keyword>menopause</keyword>
	<keyword>image</keyword>
	<keyword>FMRI</keyword>
	<keyword>Menopausal stag</keyword>
	<keyword>vasomotor symptom</keyword>
</DOC>